Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields

• Published in: Lung Vol. 202; no. 3; pp. 325 - 330
• Main Authors: Khoury, Lara M., Sheehan, Kristin N., Mariencheck, William I., Gershner, Katherine A., Maslonka, Matthew, Niehaus, Angela G., Isom, Scott, Bellinger, Christina R.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2024; Springer Nature B.V
• Subjects: Adenocarcinoma; Adenocarcinoma - pathology; Adenocarcinoma of Lung - diagnosis; Adenocarcinoma of Lung - pathology; Adequacy; Adult; Aged; Aged, 80 and over; B7-H1 Antigen - analysis; B7-H1 Antigen - metabolism; Biopsy; Bronchoscopy - methods; Carcinoma, Non-Small-Cell Lung - pathology; Cytology; Endoscopic Ultrasound-Guided Fine Needle Aspiration - methods; Female; Humans; Immunotherapy; Interventional Pulmonology; Lesions; Lung cancer; Lung Neoplasms - pathology; Male; Medicine; Medicine & Public Health; Middle Aged; Non-small cell lung carcinoma; PD-1 protein; PD-L1 protein; Pneumology/Respiratory System; Retrospective Studies; Signal transduction; Small cell lung carcinoma; Squamous cell carcinoma; Tumors; Ultrasonic imaging; Ultrasound; Bronchoscopy; Molecular markers; Lung cancer; EBUS-TBNA; PD-L1 yields
• ISSN: 0341-2040; 1432-1750; 1432-1750
• DOI: 10.1007/s00408-024-00692-4

Purpose Immunotherapy is a leading approach for treating advanced non-small cell lung cancer (NSCLC) by targeting the PD-1/PD-L1 checkpoint signaling pathway, particularly in tumors expressing high levels of PD-L1 (Jug et al. in J Am Soc Cytopathol 9:485–493, 2020; Perrotta et al. in Chest 158: 1230–1239, 2020). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive method to obtain tissue for molecular studies, including PD-L1 analysis, in unresectable tumors (Genova et al. in Front Immunol 12: 799455, 2021; Wang et al. in Ann Oncol 29: 1417–1422, 2018). This study aimed to assess the adequacy of PD-L1 assessment in EBUS-TBNA cytology specimens. Methods Data was collected retrospectively from patients who underwent EBUS-TBNA between 2017 and 2021 for suspected lung cancer biopsy. Samples positive for NSCLC were examined for PD-L1 expression. EBUS was performed by experienced practitioners, following institutional guidelines of a minimum of five aspirations from positively identified lesions. Sample adequacy for molecular testing was determined by the pathology department. Results The analysis involved 387 NSCLC cases (149 squamous cell, 191 adenocarcinoma, 47 unspecified). Of the 263 EBUS-TBNA specimens tested for PD-L1, 237 (90.1%) were deemed adequate. While 84% adhered to the protocol, adherence did not yield better results. Significantly higher PD-L1 adequacy was observed in squamous cell carcinomas (93.2%) compared to adenocarcinoma (87.6%). The number of aspirations and sedation type did not correlate with PD-L1 adequacy in either cancer type, but lesion size and location had a significant impact in adenocarcinomas. Adenocarcinoma exhibited higher PD-L1 expression (68%) compared to squamous cell carcinoma (48%). Conclusion EBUS-TBNA offers high yields for assessing immunotherapy markers like PD-L1, with satisfactory adequacy regardless of NSCLC subtype, lesion size, or location.